




2018
IATDMCT
Congress

Top science down under
16–19 September 2018 Brisbane, Australia

Scientific program

(program is subject to change)
as at 27 July 2018

Sunday 16 September 2018

13:00 – 15:00	Drugs of use and misuse, Pharmacogenetics and Pharmaco-Justice Pre congress symposium (optional) included in registration
	Room: Boulevard Auditorium
	Chair: Dr Manuela Neuman, University of Toronto Faculty of Medicine, In Vitro Drug Safety and Biotechnology, Canada
	A laboratory perspective on substance harm reduction Dr Cristiana Stefan, Centre for Addiction and Mental Health, Toronto
	Ethanol, the opioid/drug epidemic and substance abuse involvement in completed suicides Dr Frederic Hellman, Forensic Pathology Department, Ministry of Justice, Pennsylvania, USA
	Anti-depressants leading to akathisia in poor metabolizers Dr Yolande Lucire, Medical Practitioner, Australia
	Antiepileptics and hypersensitivity syndrome: Role of ethnicity and epigenetics Dr Manuela Neuman, University of Toronto Faculty of Medicine, In Vitro Drug Safety and Biotechnology, Canada
14:45 – 15:45	IATDMCT Young Scientist networking afternoon tea Boulevard foyer
16:00 – 17:30	Congress opening session
	Room: Boulevard Auditorium
	Welcome addresses Prof Andrew McLachlan, Co-chair, 2018 Congress Organising Committee
	Presidential welcome address Prof Teun van Gelder, President, IATDMCT
	Plenary presentation Clinical Toxinology - evidence to address the myths Prof Geoff Isbister, The University of Newcastle, Australia
	
17:30 – 19:00	Welcome cocktail reception Boulevard foyer
Evening	Dinner at leisure



2018 IATDMCT Congress

Top science down under

16-19 September 2018 Brisbane, Australia

Monday 17 September 2018

07:30 – 08:30	Morning roundtable sessions (optional, \$20 registration fee)		
	<p>PK/PD of commonly used antibiotics: Do plasma concentrations reflect tissue concentrations? Facilitated by Jason Roberts and Jan-Willem Alffenaar on behalf of the Anti-Infective Drugs Committee</p>	<p>Implementation of TDM in vulnerable patient groups with refractory epilepsy with case examples Chairs: Assoc Prof Cecilie Johannessen Landmark, Oslo Metropolitan University and The National Center for Epilepsy, Oslo University Hospital, Norway and Dr Arton Baftiu, Oslo Metropolitan University; The National Center for Epilepsy, Oslo University Hospital, Norway</p>	
08:45 – 10:15	Plenary presentation		
	<p>Room: Boulevard Auditorium 2018 IATDMCT C.E. Pippingier Award 2018 IATDMCT Victor Armstrong Young Investigator Award</p>		
10:15 – 10:55	Morning break, exhibition and poster viewing		
11:00 – 13:00	Concurrent session 1		
	<p>Symposium 1: Therapeutic drug monitoring of mycophenolic acid products: Evidence and knowledge gaps, laboratory and clinical experience.</p>	<p>Symposium 2: Immunogenetics and drugs of use and misuse</p>	<p>Symposium 3: Should we routinely measure unbound drug concentration?</p>
	<p>Chair: Prof Teun van Gelder, Erasmus Medical Center, The Netherlands</p>	<p>Chair: Dr Manuela Neuman, University of Toronto Faculty of Medicine, In Vitro Drug Safety and Biotechnology, Canada</p>	<p>Chair: Prof Carl Kirkpatrick, Monash University, Australia</p>
	<p>The evidence supports dosing of mycophenolic products to a target concentration: Interpreting the literature and research priorities Dr David Metz, The Royal Children's Hospital, Melbourne, Australia</p> <p>Using different analytical methods and matrices to assess the exposure of mycophenolic acid: What is the evidence? Dr Maria Shipkova, Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum-Stuttgart, Germany</p> <p>The interpretation of mycophenolic acid concentrations, considerations to be made Dr Brenda de Winter, Erasmus Medical Center, The Netherlands</p>	<p>Monoclonal antibodies monitoring: Clinical relevant aspects Dr Mario Regazzi, Italian Society of Pharmacokinetics and Biopharmaceutics, (SIFEB), Pavia, Italy</p> <p>PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease Dr Devanshi Seth, The University of Sydney; Centenary Institute of Cancer Medicine and Cell Biology, Australia</p> <p>Risk assessment in autoimmune aspect of alcoholic, non-alcoholic and viral hepatitis Dr Paul Haber, The University of Sydney, Drug Health Services, Australia</p> <p>B-cell activating factor and immunosuppression in the first year after kidney transplantation</p>	<p>Protein binding and the interpretation of drug concentrations Assoc Prof Matt Doogue, University of Otago, Christchurch, New Zealand</p> <p>Total and unbound drug concentrations in critical illness Dr Paul Chin, University of Otago, Christchurch, New Zealand</p> <p>The relevancy of drug protein binding in pregnancy Dr Rob ter Heine, Radboud University Medical Center, The Netherlands</p> <p>Determining unbound drug concentrations Dr Brett McWhinney, Royal Brisbane and Women's Hospital, Australia</p> <p>Panel discussion</p>

	<p>Clinical implementation of MPA monitoring, in transplant and beyond Prof Teun van Gelder, Erasmus Medical Center, The Netherlands</p>	<p>Prof Eberhard Wieland, Medical Center for Diagnostics, Central Institute for Clinical Chemistry and Laboratory, Germany</p> <p>Immunotoxicity associated with herbal-induced liver injury Dr Manuela Neuman, University of Toronto Faculty of Medicine, In Vitro Drug Safety and Biotechnology, Canada</p>		
13:00 – 13:55	Lunch, exhibition and poster viewing			
	<p>Shimadzu Scientific Industry workshop</p> 	<p>Joint meeting for Immunosuppressive Drugs Scientific Committee and the Biomarker Committee</p>	IATDMCT Scientific Committees meetings	
14:00 – 15:30	Concurrent session 2			
	<p>Symposium 4: Pre-emptive Pharmacogenetic testing</p> <p>Chair: Prof Mark Linder, University of Louisville School of Medicine, USA</p>	<p>Contributed papers 1: Anti-infective agents</p>	<p>Contributed papers 2: TDM in the real world</p>	<p>Contributed papers 3: Clinical Toxicology</p>
	<p>Introduction to Pre-emptive testing rationale and overview of current approaches for Implementation Prof Mark Linder, University of Louisville School of Medicine, USA</p> <p>Implementing Pharmacogenomics in Europe: Design and implementation strategy of the ubiquitous Pharmacogenomics consortium Prof Henk-Jan Guchelaar, Leiden University Medical Center, The Netherlands</p> <p>Implementation of a pre-emptive PGX testing strategy in a large US healthcare system Dr Mark Dunnenberger, NorthShore University HealthSystem, USA</p> <p>Opportunities and challenges in implementing precision medicine into pharmacy practice Dr Yan-Ting Wang, Cancer Hospital, Chinese Academy of Medical Sciences and Peking</p>	<p>Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients Assoc Prof Miao Yan, The Second Xiangya Hospital, Central South University, China</p> <p>Therapeutic drug monitoring of voriconazole Dr Jane Carland, St Vincent's Hospital, Australia</p> <p>Voriconazole for treatment of invasive fungal infection in paediatric patients: Is there need for a more frequent dosing strategy? Dr Jyoti Nehra, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India</p> <p>Posaconazole monitoring during real-life in haematological patients: Experience from a tertiary care center</p>	<p>Real-world dabigatran concentration monitoring - Christchurch experience Dr Paul Chin, University of Otago, New Zealand</p> <p>Lidocaine infusion for pain management in major surgery patients - pharmacokinetic and therapeutic drug monitoring challenges Prof Stein Bergan, Oslo University Hospital, Norway</p> <p>A time and motion study of phlebotomists' work Dr Sophie Stocker, St Vincent's Hospital, Australia</p> <p>Therapeutic monitoring of antipsychotic efficacy in schizophrenia patients by simultaneous determinations of a panel of biomarkers in plasma Assist Prof HuaLin Cai, Second Xiangya Hospital of Central South University, China</p> <p>Barriers overcome: A case study of deploying</p>	<p>Two concomitant cases of strychnine poisoning Assoc Prof, Amanda Jenkins, Umass Memorial Medical Center, USA</p> <p>Detection of synthetic opioids using high resolution mass spectrometry: Keeping up with the trends Assoc Prof Kara Lynch, University of California San Francisco, USA</p> <p>Designer benzodiazepines pharmacological effects: how to find the information? Dr Souleiman El Balkhi, University Hospital, Limoges, France</p> <p>Quantification of metformin in human serum by hydrophilic interaction liquid chromatography - mass spectrometry Dr Ahmed Abdalla, University of South Australia, Australia</p> <p>Acute intentional self-poisoning with</p>

	<p>Union Medical College, China</p> <p>Dr Mariadelfina Molinaro, Foundation IRCCS Policlinico San Matteo, Italy</p> <p>Retrospective analysis of posaconazole dosing strategy in a pediatric haematology-oncology population: Single center experience</p> <p>Dr Mariadelfina Molinaro, Foundation IRCCS Policlinico San Matteo, Italy</p> <p>An international survey on the practice of therapeutic drug monitoring of antifungal drugs</p> <p>Dr Subhosmito Chakraborty, Tata Medical Center, India</p>	<p>model-informed precision dosing across five continents and 50+ sites</p> <p>Dr Robert McLeay, DoseMe, Australia</p> <p>Evaluation of the pharmacokinetics of psychotropic drugs in HIV-infected patients: Implications for clinical practice</p> <p>Dr Dario Cattaneo, Luigi Sacco University Hospital, Milan, Italy</p>	<p>pesticides: Presentation of two cases and risk factors for severity</p> <p>Dr Nicolas Venisse, CIC INSERM 1402 and CHU Poitiers, France</p> <p>Amodiaquine and the reactive metabolite activate inflammasomes leading to amodiaquine-induced liver injury and agranulocytosis</p> <p>Assoc Prof Ryuji Kato, Osaka University of Pharmaceutical Sciences, Japan</p>
15:30 – 15:55	Afternoon break, exhibition and poster viewing		
16:00 – 17:30	Concurrent session 3		
	<p>Symposium 5: TDM for antiviral agents</p> <p>Chair: Prof Anders Asberg, University of Oslo, Norway</p> <p>Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus</p> <p>Dr Dario Cattaneo, Luigi Sacco University Hospital, Milan, Italy</p> <p>TDM for valganciclovir in patients with poor renal function after transplantation</p> <p>Prof Teun van Gelder, Erasmus MC, Rotterdam, The Netherlands</p> <p>Therapeutic drug monitoring for ribavirin in patients with hepatitis E</p> <p>Prof Pierre Marquet, Université de Limoges, France</p>	<p>Symposium 6: Education in TDM and CT</p> <p>Chair: Staffan Rosenborg, Karolinska University Hospital, Sweden</p> <p>Educating future clinical toxicologists</p> <p>Dr Eric Franssen, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands</p> <p>Clinical education of Therapeutic Drug Monitoring</p> <p>Prof Jennifer Martin, The University of Newcastle, Australia</p>	<p>Symposium 7: Microsampling and dried blood spot analysis</p> <p>Chair: Dr Marieke G.G. Sturkenboom, University Medical Center Groningen, The Netherlands</p> <p>Patient Centric Blood Sampling – What is it and where might it be taking us?</p> <p>Dr Neil Spooner, Spooner Bioanalytical Solutions, UK</p> <p>Dried blood spot; when will it become standard of care?</p> <p>Dr Marieke G.G. Sturkenboom, University Medical Center Groningen, The Netherlands</p> <p>Microsampling in critically ill patients</p> <p>Dr Suzanne Parker, The University of Queensland, Centre for Clinical Research, Australia</p>
17:30 – 19:00	Cocktail reception and poster viewing		
19:00	<p>Young Scientists Dinner</p> <p>South Beach Social, 30aa Plaza Parklands, South Bank</p>		




2018
IATDMCT
Congress

Top science down under

16–19 September 2018 Brisbane, Australia

Tuesday 18 September 2018

07:30 – 08:30	Morning roundtable sessions (optional, \$20 registration fee)		
	<p>Controversy around vancomycin target to achieve optimal therapeutic effect: Trough only or both peak and trough levels, AUC/MIC ratio versus C_{max}/MIC ratio: Where is the evidence based practice? Facilitated by Dr Hundie Tesfaye, Motol University Hospital; Charles University, Prague, Czech Republic</p>	<p>Identification and handing of pharmacokinetic interactions of antiepileptic – and psychoactive drugs by TDM and databases Chairs: Assoc Prof Cecilie Johannessen Landmark, Oslo University Hospital, Norway, Dr Arton Baftiu, Oslo University Hospital, Norway and Dr Tore Haslemo, Diakonhjemmet Trust Hospital, Oslo, Norway</p>	<p>Hematocrit and dried blood microsampling: Still an issue? Chair: Dr Marieke G.G. Sturkenboom, University Medical Center Groningen, The Netherlands and Prof Christophe Stove, Ghent University, Belgium</p>
08:30 – 09:30	IATDMCT AGM		
09:30 – 10:00	Plenary presentation		
10:00 – 10:15	Consensus Guidelines 2017 for TDM in Neuropsychopharmacology Prof Werner Steimer, Munich University of Technology, Germany		
10:15 – 10:55	Morning break, exhibition and poster viewing		
11:00 – 13:00	Concurrent session 4		
	<p>Symposium 8: Medicalization and legalization of Cannabis: Short and long-term consequences Chair: Prof Jennifer Martin, The University of Newcastle, Australia</p> <p>Setting the scene – Australia and the world – current regulation status, agriculture regulations and drug development Prof Jennifer Martin, The University of Newcastle, Australia</p> <p>TDM/Clinical evidence for using cannabis – international trials Prof Victor Novak, Internal Medicine Physician, Israel</p> <p>Issues around taking a plant into clinical practice Dr Peter Galettis, The University of Newcastle, Australia</p>	<p>Symposium 9: Dosing decision support tools in special populations: Paediatrics Chairs: Assoc Prof Catherine Sherwin, University of Utah School of Medicine, USA and Dr Hesh Al-Sallami, University of Otago, New Zealand</p> <p>Medicine dose-response(s) in children translated into algorithms: population vs individual Dr Hesh Al-Sallami, University of Otago, New Zealand</p> <p>Application of decision support tools in hospitals Dr Stefanie Hennig, The University of Queensland, Australia</p> <p>Development of dosing support tools for paediatric diseases Prof Catherine Knibbe, University of Leiden, The Netherlands</p> <p>Evaluation and integration dosing tools in special populations Assoc Prof Catherine Sherwin, University of Utah School of Medicine, USA</p> <p>Panel discussion</p>	<p>Symposium 10: <i>Staphylococcus aureus</i> blood stream infection mortality is still 30%: Could TDM make a difference? Chair: Prof Deborah Marriott, St Vincent's Hospital, Australia</p> <p>Can we do better? Optimising beta-lactam therapy in <i>S. aureus</i> bacteraemia Prof Deborah Marriott, St Vincent's Hospital, Australia</p> <p>Linezolid and telizolid: Is there a role for guided dose optimisation? Dr Dario Cattaneo, Luigi Sacco University Hospital, Milan, Italy</p> <p>Vancomycin: Innovative approaches to getting it right Dr Michael Neely, University of Southern California, USA</p> <p>Alternative treatment options for <i>S. aureus</i> infection Dr Natasha Holmes, The Austin Hospital, Australia</p>

13:00 – 13:55	<p>Lunch, exhibition and poster viewing</p> <p>Waters Corporation Industry workshop: Approach for Analysing Infiximab in Serum by LC-MS/MS in TDM Dominic Foley, Senior Scientist, Clinical Scientific Operations, Waters Corporation, Wilmslow, UK Transitioning research based TDM assays into a high-through-put clinical service Dr Brett McWhinney, Analytical Chemistry Unit, Chemical Pathology, Pathology Queensland, Herston Hospitals</p>  <p>IATDMCT Scientific Committees meetings</p>		
14:00 – 15:30 Concurrent session 5			
	<p>Contributed papers 4: Pharmacogenetics and personalised medicine</p> <p>Impact of recipient and donor pharmacogenetics on acute rejection in kidney transplantation Ms Rong Hu, The University of Adelaide, Australia</p> <p>Antipsychotic-Induced Weight Gain is associated with FTO gene variants rs9939609 and rs7185735 Prof Werner Steimer, Munich University of Technology, Germany</p> <p>Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines Prof Laure Elens, Université Catholique de Louvain, Belgium</p> <p>Genetic polymorphisms modulating CYP2D6 and P-glycoprotein activities have a major effect on analgesic efficacy of intrathecal morphine involving pharmacokinetic changes Dr Wangjun Qin, China-Japan Friendship Hospital, China</p> <p>Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients Dr Nadia Ben Fredj, University of Monastir, Tunisia</p> <p>Personalized infliximab dosing in inflammatory bowel diseases: Pharmacokinetic-based therapeutic drug monitoring Dr Núria Padullés, Hospital Universitari Bellvitge, Spain</p>	<p>Contributed papers 5: Pharmacometrics</p> <p>Proposed strategy to refine the phenotyping approach and its implementation to predict drug clearance Mr Jeffry Adiwidjaja, The University of Sydney, Australia</p> <p>A limited sampling strategy for Bayesian estimation of intracellular everolimus exposure in renal transplant recipients Dr Ida Robertsen, University of Oslo, Norway</p> <p>A predictive model of ribavirin pharmacokinetics in lung transplant recipients providing guidance for effective dosing Dr Eliza Milliken, St Vincent's Hospital, Australia</p> <p>Pharmacokinetic modeling and cardiovascular tolerance of intravenous sildenafil in newborns with congenital diaphragmatic hernia Dr Brenda de Winter, Erasmus Medical Center, The Netherlands</p> <p>Prediction of CYP3A metabolic phenotype in patients with ziprasidone by blood concentration measurement Dr Yan Zhang, Xi'an Mental Health Center, China</p>	<p>Contributed papers 6: TDM in Oncology</p> <p>The cost-effectiveness of Therapeutic Drug Monitoring (TDM) of generic imatinib for the treatment of Chronic Myelogenous Leukemia (CML) Dr Salvatore Salamone, Saladax Biomedical, USA</p> <p>Establishment of a national Therapeutic Drug Monitoring (TDM) service for the treatment of challenging childhood cancer patient populations Dr Gareth Veal, Newcastle University, UK</p> <p>Association of fludarabine exposure and survival after allogeneic cell transplantation: rRetrospectively estimated and prospectively simulated Dr Erik van Maarseveen, University Medical Center Utrecht, Netherlands</p> <p>Paracetamol use prior to HCT conditioning has a significant effect on the within-patient busulfan pharmacokinetics over time. Dr Erik van Maarseveen, University Medical Center Utrecht, Netherlands</p> <p>Regorafenib pharmacokinetics and exposure-toxicity relationship in Japanese cancer patients Assoc Prof Masahide Fukudo, Asahikawa Medical University, Japan</p>
15:30 – 15:55	Afternoon break, exhibition and poster viewing		

16:00 – 17:30		Concurrent session 6	
	<p>Symposium 11: Alternative matrix for the determination of human exposure to environmental pollutants</p> <p>Chair: David W. Kinniburgh, Alberta Centre for Toxicology, University of Calgary, Canada</p>	<p>Symposium 12: Debate – Genotyping of cancer tissue to advise choice of chemotherapy is pharmacologically unsafe</p> <p>Chair: Prof Euan Walpole, Head of Cancer Services, Brisbane, Australia</p>	<p>Symposium 13: The translational science of antidoping – investigating pure performance</p> <p>Chairs: Prof Andrew McLachlan, Australia’s Antidoping Rule Violation Panel and Dr Naomi Speers, Australian Sports Antidoping Authority, Australia</p>
	<p>Breast milk for the estimation of neonatal and lactational exposure to environmental pollutants Prof Jochen Mueller, The University of Queensland, Australia</p> <p>Adipose tissue as a site of environmental pollutants accumulation Dr Nicolas Venisse, University Hospital, Poitiers, France</p> <p>Pesticide residues analysis in food matrices Dr Souleiman El Balkhi, Limoges University Hospital, France</p>	<p>Affirmative: Prof Paul De Souza, University of Western Sydney, Australia; Prof Howard Gurney, Macquarie University, Australia; Prof Michael Michael, Peter Macallum Cancer Institute, Australia</p> <p>Negative: Prof David Thomas, The Kinghorn Cancer Centre, Australia; Dr Erik Van Maarseveen, University Medical Center Utrecht, The Netherlands; Dr Jessica Ryan, Hunter New England Local Health District and University of Newcastle, Australia</p>	<p>Analytical innovations in antidoping – staying ahead of the cheats Daniel Eichner, Sports Medicine Research and Testing Laboratory (SMRTL), Salt Lake City, Utah, USA</p> <p>Translational antidoping – track to the clinic Prof David Handelsman (TBC), ANZAC Research Institute and WADA Health Medical Research Committee</p> <p>Innovations and logistics – delivering a modern testing program for the games Dr Catrin Goebel (TBC), Australian Sports Drug Testing Laboratory, Australia</p>
17:30 – 18:30	IATDMCT Young Scientists committee meeting		
19:00 – 23:00	<p>Congress dinner Boulevard Room, The Brisbane Convention & Exhibition Centre</p>		



2018
IATDMCT
Congress

Top science down under

16-19 September 2018 Brisbane, Australia

Wednesday 19 September 2018

07:30 – 08:30		Morning roundtable sessions (optional, \$20 registration fee)	
		<p>Renal replacement therapy modalities and the PK of antimicrobial agents Facilitated by Assoc Prof Darren Roberts on behalf of the Anti-Infective Drugs Committee</p>	<p>How do we do better to deal with dosing errors in children? Chair: Dr Hesham Al-Sallami, University of Otago, New Zealand</p> <p>Understanding the pharmaco-epidemiology of medication errors in children Dr Geert't Jong, Children's Hospital Research Institute of Manitoba, Canada</p> <p>The pros and cons of dose scaling and dosing errors in children Assoc Prof Catherine Sherwin, University of Utah School of Medicine, USA</p> <p>Roundtable discussion:</p> <ul style="list-style-type: none"> Recording and preventing dosing errors in children in your workplace (for clinicians) Current projects around reporting and preventing dosing errors in children (for clinicians and researchers)
08:30 – 10:00		Concurrent session 7	
	<p>Contributed papers 7: Immunosuppressants</p> <p>High tacrolimus clearance is associated with development of interstitial fibrosis and tubular atrophy in the transplanted kidney Mr Erlend J Egeland, University of Oslo, Norway</p> <p>Pharmacokinetic differences between morning and evening administration of tacrolimus in renal transplant recipients – described by a double absorption-phase model Ms Marte Theie Gustavsen, Oslo University Hospital, Norway</p> <p>Association of infliximab concentrations with clinical response in psoriasis Dr Núria Padullés, Hospital Universitari Bellvitge, Spain</p> <p>Association of pharmacokinetic and pharmacodynamic markers of mycophenolic acid and clinical outcomes in cord blood transplant patients</p>	<p>Contributed papers 8: Clinical Toxicology</p> <p>A novel activity-based concept to screen biological matrices for the presence of (synthetic) opioids Dr Annelies Cannaeert, UGent - Laboratory of Toxicology, Belgium</p> <p>Futility of urine salbutamol doping control, demonstrated through pharmacometrics Dr Sven C van Dijkman, Centre for Human Drug Research, Netherlands</p> <p>Routine toxicology analysis including NPS using GC/MS and LC-ion trap MS Dr Gina Chew, Health Sciences Authority, Singapore</p> <p>Metabolism of new psychoactive substances studied by metabolomic techniques? A proof of concept study Mr Sascha K Manier, Saarland University, Germany</p> <p>Heavy metals in herbo-mineral formulations in patients</p>	<p>Contributed papers 9: Anti-infective drugs</p> <p>Loss of control of HIV viremia with OTC weight-loss drugs: A call for caution? Dr Dario Cattaneo, Luigi Sacco University Hospital, Milan, Italy</p> <p>The effectiveness and safety of individualized vancomycin dosing via pharmacokinetic monitoring in critically ill patients Miss Na He, Peking University Third Hospital, China</p> <p>Vancomycin – Improving prescribing practices Dr Sophie Stocker, St Vincent's Hospital, Australia</p> <p>Development of $f_{T>MIC}$ calculation model and its application in individualized medication optimization of carbopenems in critical care patients Dr Wenqian Chen, China-Japan Friendship Hospital, China</p>

	<p>Assoc Prof Ikuko Yano, Kobe University Hospital, Japan</p> <p>Evaluation of a volumetric absorptive microsampling device for tacrolimus measurement in routine drug monitoring Dr Phillip Morgan, King's College Hospital, UK</p> <p>Determination of cyclosporine A following renal transplantation: CMIA or LC-MS/MS? Mrs Wang Xiaoxue, China-Japan Friendship Hospital, China</p>	<p>undergoing cancer chemotherapy: A tertiary care cancer hospital experience Dr Manjunath Nookala Krishnamurthy, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India</p> <p>Parabens exposure during pregnancy: Determination in urine of pregnant women from the French EDDS cohort study Dr Nicolas Venisse, CIC INSERM 1402 and CHU Poitiers, France</p>	<p>Beta-lactam concentrations inadequate? Try a gout drug! A case series of probenecid boosting of flucloxacillin 24 hour infusions Ms Cindy Lau, St Vincent's Hospital, Australia</p>
10:00 – 10:30	Morning tea		
10:30 – 12:30	Concurrent session 8		
	<p>Symposium 14: Emerging TDM technologies and obstacles to widespread use Facilitated by ISoP/ACCP Clinical Pharmacometrics Special Interest Group</p> <p>Chair: Dr Michael Neely, University of Southern California, USA</p>	<p>Symposium 15: Screening for novel psychoactive drugs in clinical and post mortem toxicology</p> <p>Chair: Dr Eric JF Franssen, OLVG Hospital, Amsterdam, The Netherlands</p>	<p>Symposium 16: IATDMCT Young Scientist Symposium</p> <p>Chairs: Dr Brenda de Winter, Erasmus Medical Center, The Netherlands and Dr Indy Sandaradura, Westmead Hospital, Australia</p>
	<p>Adaptive Feedback Control (& TDM) need NOT just be based on PK data Dr Gauri Rao, University of North Carolina, USA</p> <p>Clinical applications of population pharmacokinetic models of antibiotics Dr Brenda de Winter, Erasmus Medical Center, The Netherlands</p> <p>Overcoming obstacles to practical, model-based prescribing Dr Michael Neely, University of Southern California, USA</p> <p>Evidence of and barriers to TDM-based precision dosing of oncology drugs Prof Yusuke Tanigawara, Keio University School of Medicine, Tokyo, Japan</p> <p>Widespread TDM implementation - You can lead a horse to water... Prof Deborah Marriott, Dr Sophie Stocker, Dr Jane Carland, St Vincent's Hospital, Australia</p>	<p>Novel psychoactive substances in the Netherlands and beyond: Challenges for clinical toxicology and pharmacology Dr Tibor Brunt, Amsterdam Institute for Addiction Research, The Netherlands</p> <p>How to detect Novel Psychoactive Substances in a clinical setting? Dr Eric JF Franssen, OLVG Hospital, Amsterdam, The Netherlands</p> <p>Post mortem toxicology screening in a forensic setting Dr Peter Zweipfenning, KKG, The Hague, The Netherlands and MVZ Dr Stein & Kollegen, Mönchengladbach, Germany</p> <p>Interactive panel discussion</p>	<p>Evaluation of the Capitainer device as a new haematocrit independent alternative for dried blood spot collection Prof Christophe Stove, Ghent University, Belgium</p> <p>Role of LC-MS associated matrix effects and ion suppression in TDM and CT Mr Thomas Bambauer, Saarland University, Germany</p> <p>Research since winning award and career advice Dr Dennis Hesselink, Erasmus MC, Rotterdam, The Netherlands</p>

12:30 – 13:30	Lunch	
13:30 – 14:30	Plenary presentation and congress close	
	Plenary presentation Tackling antibiotic resistance by targeting virulence not viability Prof Jennifer Martin, Griffith Institute for Drug Discovery (GRIDD), Griffith University, Australia	
14:30 – 16:30	Post congress workshops (optional) included in registration	
	Bayesian-based Therapeutic Drug Monitoring (TDM) – Concepts and Applications Chairs: Dr Michael Neely, University of Southern California, USA and Prof Pierre Marquet, University of Limoges, France	Medicalization and legalization of Cannabis: Hot topics Chair: Prof Jennifer Martin, The University of Newcastle, Australia
	Part 1: Basic Concepts Dr Elizabeth Lakota, Institute for Clinical Pharmacodynamics, USA Part 2: Current Applications of Bayesian-based TDM Bayesian based tacrolimus dosing utilizing patient centered sampling Dr Anders Asberg, Oslo University, Norway The way to and lessons from >100,000 online Bayesian dose adjustments of immunosuppressants Prof Pierre Marquet, University of Limoges, France Integrating pharmaco and bacterial dynamics and immunology into optimizing antibiotic therapy Dr Gauri Rao, University of North Carolina Eshelman School of Pharmacy, USA Part 3: Moving Forward Dr Michael Neely, University of Southern California, USA	Cannabis and other drug interactions – usefulness of TDM Assoc Prof Jennifer Schneider, The University of Newcastle, Australia Cannabinoid pharmacology Dr Catherine Lucas, The University of Newcastle, Australia Synthetic cannabinoids – new technologies Ms Michelle Williams, The University of Newcastle, Australia Issues with pharmacometrics/ PKPD modelling and cannabinoids Dr Zheng Liu, The University of Newcastle, Australia